stroke
(2)
CORXEL Pharmaceuticals
CORXEL Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative therapies for cardiometabolic diseases worldwide. Spun out of RTW Investments in 2019 (formerly JiXing Pharmaceuticals) and dual-based in Berkeley Heights, New Jersey and Shanghai, CORXEL is advancing a pipeline led by CX11, a differentiated oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, alongside JX10 for acute ischemic stroke and JX09 for hypertension. In January 2026 the company raised up to $287 million in Series D1 financing to push these programs through late-stage clinical trials.
RapidAI
RapidAI builds FDA-cleared clinical AI software that reads CT, CTA, CT perfusion and MRI scans to flag stroke, aneurysms and pulmonary embolisms in minutes - giving hospital teams a faster path to treatment. The platform began life as the Stanford spin-out iSchemaView and now runs in more than 2,000 hospitals across 100+ countries.